Skip to content

Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment

Radiofrequency Ablation for Hepatocellular Carcinoma Using Gradual Radiofrequency (RF) Energy Delivery Mode With Octopus Electrodes: A Prospective Observational Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05397860
Enrollment
120
Registered
2022-05-31
Start date
2020-01-06
Completion date
2023-08-30
Last updated
2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Liver Disease, Hepatocellular Carcinoma, Liver Cirrhosis

Keywords

Radiofrequency ablation, Gradual radiofrequency energy increment, Cone-unit ablation

Brief summary

To evaluate local tumor progression rate at 12 months after percutaneous radiofrequency ablation with gradual radiofrequency energy delivery mode with Octopus electrodes in patients with hepatocellular carcinoma.

Interventions

PROCEDURERadiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes

Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.

Sponsors

Starmed
CollaboratorINDUSTRY
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Child-Pugh Class A or B * chronic hepatitis B or liver cirrhosis * contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) within 60 days of scheduled radiofrequency ablation (RFA) date * clinically diagnosed hepatocellular carcinoma (HCC), equal or less than 4 cm

Exclusion criteria

* number of HCC, equal or more than 3 * largest tumor size over 4 cm * Child-Pugh class C * presence of vascular invasion by HCC * platelet count less than 40,000 per mm3 or International Normalized Ratio (INR) prolongation over 50% * presence of extrahepatic metastasis

Design outcomes

Primary

MeasureTime frameDescription
Local tumor progression rate12 months after radiofrequency ablation (RFA)Evaluate local tumor progression by follow-up computed tomography (CT) or magnetic resonance imaging (MRI) with alpha-fetoprotein (AFP) level

Secondary

MeasureTime frameDescription
Success rate of cone-unit ablationImmediately after radiofrequency ablation (RFA)The cone-unit ablation is defined as complete ablation of tumor with safety margin and occlusion of the 4th or 5th branches of portal vein.

Countries

South Korea

Contacts

Primary ContactHyun Hee Lee
redlion55@naver.com82-2-2072-4177
Backup ContactJae Hyun Kim, M.D.
yyssaa21@gmail.com82-2-2072-2519

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026